Tirzepatide is a dual agonist of GLP-1 and GIP receptors, researched for its role in glucose-dependent insulin secretion and metabolic regulation. Preclinical and clinical investigations have examined its potential in models of type 2 diabetes and obesity, focusing on glycemic control, weight reduction, and cardiovascular risk factors through enhanced incretin effects. Studies highlight its influence on appetite suppression, insulin sensitivity, and lipid metabolism in animal models. This peptide is utilized in metabolic and endocrinological research settings.
For research use only.